TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodie

Sponsor: CSL Behring · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 35 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,631,010

Rescue Site Savings

+$3,729,630

Unlock Full NCT06003387 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06003387 Rescue Dossier →